INCY · Business segments
Incyte (INCY) revenue by segment
Where Incyte’s revenue comes from, as reported in its SEC filings.
Latest quarter: September 30, 2026
Total revenue on the income statement: $1.56B.
Revenue by Product
| Line | Revenue | Share |
|---|---|---|
| Jakafi | $826.5M | 53.1% |
| Opzelura | $254.9M | 16.4% |
| JAKAVI Royalty Revenues | $132.5M | 8.5% |
| Niktimvo | $67.4M | 4.3% |
| Zynyz | $58.3M | 3.7% |
| Minjuvi/Monjuvi | $54.6M | 3.5% |
| Milestone and Contract Revenues | $49.8M | 3.2% |
| OLUMIANT Royalty Revenues | $39.1M | 2.5% |
| Iclusig | $33.5M | 2.2% |
| Pemazyre | $21.2M | 1.4% |
| Other Product Royalty Revenues | $12.6M | 0.8% |
| TABRECTA Royalty Revenues | $6.8M | 0.4% |
Revenue by Geography
| Line | Revenue | Share |
|---|---|---|
| United States | $1.43B | 92.2% |
| Europe | $107.4M | 6.9% |
| Other Countries | $14.9M | 1.0% |
Latest year: December 31, 2025
Total revenue on the income statement: $5.14B.
Revenue by Product
| Line | Revenue | Share |
|---|---|---|
| Jakafi | $3.09B | 60.2% |
| Opzelura | $678.5M | 13.2% |
| JAKAVI Royalty Revenues | $457.7M | 8.9% |
| Niktimvo | $151.6M | 2.9% |
| Milestone and Contract Revenues | $150M | 2.9% |
| Olumiant Royalty | $144.6M | 2.8% |
| Minjuvi/Monjuvi | $144.6M | 2.8% |
| Iclusig | $134.1M | 2.6% |
| Pemazyre | $86.7M | 1.7% |
| Zynyz | $66.4M | 1.3% |
| TABRECTA Royalty Revenues | $26.7M | 0.5% |
| Other Product Royalty Revenues | $7.9M | 0.2% |
Revenue by Geography
| Line | Revenue | Share |
|---|---|---|
| United States | $4.8B | 93.4% |
| Europe | $323.7M | 6.3% |
| Other Countries | $17.6M | 0.3% |
Reading notes
Share is each line’s part of that breakdown. Margin is the company’s reported segment operating income divided by that segment’s revenue. Companies define segment profit differently and may re-cut segments over time, so a company’s lines can differ between years. Breakdowns that do not add up to within 5% of reported revenue are left out.